Insulet | PODD - Equity Capital And Reserves


Insulet reported $1.42B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Align Technology USD 4.23B 83.03M Jun/2026
AtriCure USD 516.43M 24.74M Jun/2026
Baxter International USD 6.21B 163M Jun/2026
Becton, Dickinson and Co. USD 24.13B 1.15B Mar/2026
Boston Scientific USD 24.93B 934M Jun/2026
Cardinal Health USD -2.83B 52M Mar/2026
Cooper Companies USD 8.36B 124.7M Dec/2025
Dexcom USD 2.62B 335.5M Jun/2026
Edwards Lifesciences USD 10.62B 290.5M Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Globus Medical USD 4.73B 159.06M Mar/2026
ICU Medical USD 2.11B 11.9M Mar/2026
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.42B 119.6M Jun/2026
Integra LifeSciences USD 1.04B 971K Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Medtronic USD 48.99B 128M Dec/2025
Merit Medical Systems USD 1.68B 53.08M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Solventum Corp USD 4.8B 169M Jun/2026
Stryker USD 22.98B 559M Mar/2026
Tandem Diabetes Care USD 132.4M 22.77M Mar/2026
Teleflex USD 3.08B 40.33M Mar/2026
West Pharmaceutical Services USD 2.99B 200K Jun/2026
Zimmer Biomet Holdings USD 12.63B 49.1M Jun/2026